Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.81
+0.18 (3.20%)
At close: Apr 28, 2026, 4:00 PM EDT
5.92
+0.11 (1.89%)
After-hours: Apr 28, 2026, 6:06 PM EDT
Lexeo Therapeutics Employees
Lexeo Therapeutics had 59 employees as of December 31, 2025. The number of employees decreased by 13 or -18.06% compared to the previous year.
Employees
59
Change (1Y)
-13
Growth (1Y)
-18.06%
Revenue / Employee
n/a
Profits / Employee
-$1,694,254
Market Cap
430.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 59 | -13 | -18.06% |
| Dec 31, 2024 | 72 | 14 | 24.14% |
| Dec 31, 2023 | 58 | 34 | 141.67% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Neurogene | 131 |
| Invivyd | 122 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 96 |
| Century Therapeutics | 78 |
| Assembly Biosciences | 73 |
| Armata Pharmaceuticals | 60 |
LXEO News
- 1 day ago - Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - GlobeNewsWire
- 4 weeks ago - Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 7 weeks ago - Lexeo Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Lexeo Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts
- 2 months ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewsWire
- 3 months ago - Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics - GlobeNewsWire